Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAIN: Secukinumab dosage interval shortening in psoriasis
NCT02474069Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2015
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Feb 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02474069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02474069.